Genpact
G
33.65
+0.20
+0.60%
Genpact
US · G
#2004 by market cap
Listed 1970
33.65
+0.20
+0.60%
Live - 5344 symbols - heartbeat 31s ago
· 2026-10-07 20:02
After-hours
33.25
-1.19%
- Market cap
- 5.63B
- P/E (TTM)i
- 10.01
- P/Bi
- 2.16
- EPSi
- 3.13
- Div yieldi
- 2.12%
- 52W posi
- 33%
Reader sentiment
Are you bullish or bearish on G?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 4 in the most recent period (2026/Q3).
- Total institutional ownership fell 0.9 percentage points.
Institutional ownership
- Held by institutions
- 108.76% -0.89pp
- Institutions
- 566 -4
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund79.80%
Hedge Fund12.83%
VC/PE Fund8.68%
Public Company2.02%
Government Pension Fund1.90%
Private Company1.52%
Sovereign Wealth Fund1.16%
Individual/Insider0.92%
Family Office/Trust0.40%
Top holders as of 2026-06-30
BlackRock
9.43% · 15.84M sh
Nalanda Capital Pte Ltd
8.15% · 13.70M sh
Vanguard Portfolio Management, LLC
6.13% · 10.30M sh
FMR
6.05% · 10.17M sh
AQR Capital Management
5.11% · 8.59M sh
Vanguard Capital Management, LLC
5.06% · 8.51M sh
Dimensional Fund Advisors
3.75% · 6.30M sh
J.P. Morgan Asset Management, Inc.
3.37% · 5.66M sh
Geode Capital Management, LLC
3.17% · 5.33M sh
State Street Global Advisors
3.17% · 5.33M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Nallicheri Tyagarajan | Chief Executive Officer | 0.34% |
| Balkrishan Kalra | Senior Vice President OF Financial Services, Consumer & Healthcare | 0.11% |
| Piyush Mehta | Chief Human Resources Officer & Senior VP | 0.09% |
| Michael Weiner | Senior Vice President | 0.06% |
| Riju Vashisht | Chief Growth Officer | 0.04% |
| Anil Nanduru | Senior VP and Global Business Leader of High Tech & Manufacturing, Consumer & Healthcare | 0.04% |
| Laura Conigliaro | Independent Director | 0.04% |
| Mark Verdi | Independent Director | 0.04% |
| James Madden | Independent Chairperson | 0.03% |
| CeCelia Morken | Independent Director | 0.03% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-13 | Balkrishan Kalra | Senior Vice President OF Financial Services, Consumer & Healthcare | Open Market Disposition | -10,000 | $36.79 |
| 2026-09-08 | Sumita Pandit | Senior Vice President | Other Acquisition | +76,713 | -- |
| 2026-08-18 | Anil Nanduru | Senior VP and Global Business Leader of High Tech & Manufacturing, Consumer & Healthcare | Open Market Disposition | -6,191 | $37.03 |
| 2026-08-13 | Sameer Dewan | Senior VP & Global Business Leader | Open Market Disposition | -14,972 | $34.10 |
| 2026-08-12 | Michael Weiner | Senior Vice President | Open Market Disposition | -5,900 | $34.04 |
| 2026-08-11 | Anil Nanduru | Senior VP and Global Business Leader of High Tech & Manufacturing, Consumer & Healthcare | Open Market Disposition | -29,095 | $33.92–33.96 |
| 2026-08-11 | Anil Nanduru | Senior VP and Global Business Leader of High Tech & Manufacturing, Consumer & Healthcare | Intent to Sell (Form 144) | -11,852 | $33.92 |
| 2026-08-10 | Anil Nanduru | Senior VP and Global Business Leader of High Tech & Manufacturing, Consumer & Healthcare | Intent to Sell (Form 144) | -17,243 | $33.96 |
| 2026-04-22 | Mark Verdi | Independent Director | Other Acquisition | +6,521 | -- |
| 2026-04-22 | James Madden | Independent Chairperson | Other Acquisition | +9,999 | -- |
| 2026-04-22 | CeCelia Morken | Independent Director | Other Acquisition | +6,521 | -- |
| 2026-04-22 | Brian Stevens | Independent Director | Other Acquisition | +6,521 | -- |
| 2026-04-22 | John Hinshaw | Director | Other Acquisition | +6,521 | -- |
| 2026-04-22 | Laura Conigliaro | Independent Director | Other Acquisition | +6,521 | -- |
| 2026-04-22 | Nicholas Gangestad | Director | Other Acquisition | +6,521 | -- |
| 2026-04-22 | Carol Lindstrom | Independent Director | Other Acquisition | +6,521 | -- |
| 2026-04-22 | Thimaya Subaiya | Director | Other Acquisition | +6,521 | -- |
| 2026-03-09 | Piyush Mehta | Chief Human Resources Officer & Senior VP | Sale to Issuer | -5,702 | $38.92 |
| 2026-03-09 | Balkrishan Kalra | Senior Vice President OF Financial Services, Consumer & Healthcare | Sale to Issuer | -13,893 | $38.92 |
| 2026-03-09 | Michael Weiner | Senior Vice President | Sale to Issuer | -7,019 | $38.92 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-07 20:02:43 · For reference only, not investment advice and not tailored to your situation.